Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)

Sponsor

Peking Union Medical College Hospital (Other)

Overall Status

Recruiting

CT.gov ID

NCT03145675

Collaborator

(none)

376

Enrollment

Location

Arms

52.7

Anticipated Duration (Months)

7.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The OPTIENOX-PCI is a single-center, prospective, randomized, open-label, controlled study, which is designed to assess the anticoagulation profile of: 1) High-dose (0.75 mg/kg) vs. Standard-dose (0.5 mg/kg) enoxaparin; 2) Staged-dose (0.5+0.25 mg/kg) vs. Single-dose (0.75 mg/kg) enoxaparin in about 376 patients who plan to undergo elective trans-radial coronary angiography (CAG) with or without subsequent percutaneous coronary intervention (PCI).

Condition or Disease	Intervention/Treatment	Phase
Coronary Artery Disease Percutaneous Coronary Intervention	Drug: Enoxaparin (Staged-dose PCI Group) Drug: Enoxaparin (Single-dose PCI Group) Drug: Enoxaparin (High-dose Group) Drug: Enoxaparin (Standard-dose Group)	Phase 4

Detailed Description

Once the radial sheaths are successfully inserted, eligible patients will be consecutively, sequentially, and randomly assigned in a 1:1 ratio and with a block size of 4 to either the Planned Single-dose group (0.75 mg/kg) or the Planned Staged-dose group (0.5 ± 0.25 mg/kg).

The first dose enoxaparin will be administered immediately after randomization. In the Planned Single-dose group, enoxaparin 0.75 mg/kg will be given to all patients before CAG irrespective of whether they will undergo subsequent PCI or not. In the Planned Staged-dose group, enoxaparin 0.5 mg/kg will be administered to all patients before CAG and additional 0.25 mg/kg will be given only to those who will undergo subsequent PCI immediately before PCI.

Trans-radial CAG will be performed immediately after the first dose enoxaparin is given. When the angiographic results are available, whether the patients will proceed to subsequent PCI or not will be at the discretion of the procedure operators, who are blinded to the assignment of enoxaparin dosing regimens. Patients who undergo CAG alone in each group will be defined as the High-dose (0.75 mg/kg) and the Standard-dose (0.5 mg/kg) groups, respectively; while, patients who undergo both CAG and subsequent PCI in each group will be defined as the Single-dose PCI (0.75 mg/kg) and the Staged-dose PCI (0.5 + 0.25 mg/kg) groups, respectively.

Anti-Xa levels will be assessed: 1) at 0 min (immediately before), 10 min and 90 min after the first dose enoxaparin is given (CAG-0 min, CAG-10 min, and CAG-90 min, respectively) in all patients; 2) at 0 min (immediately before) and 10 min after the beginning of PCI (PCI-0 min and PCI-10 min, respectively), and at the end of PCI (PCI-End) in patients undergoing PCI.

Target anticoagulation is defined as: 1) anti-Xa level of 0.5-1.8 IU/ml in patients in the High-dose and Standard-dose groups; 2) anti-Xa level of 0.5-1.2 IU/ml before PCI and anti-Xa level of 0.5-1.8 IU/ml from the beginning of PCI up to 90 min after the first dose enoxaparin is given in the Single-dose PCI and the Staged-dose PCI groups.

The information on cardiac ischemic and bleeding events will be collected 24 h after randomization.

The OPTIENOX-PCI study will assess the anticoagulation profile between: 1) the High-dose and the Standard-dose groups (0.75 mg/kg vs. 0.5 mg/kg); 2) the Staged-dose PCI and the Single-dose PCI groups (0.5+0.25 mg/kg vs. 0.75 mg/kg). The result of the present study will provide pharmacodynamical data for the design of future outcome studies.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

376 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Eligible patients are randomly assigned into the Planned Staged-dose Group and the Planned Single-dose Group. All patients in the Planned Staged-dose Group will receive enoxaparin 0.5 mg/kg at the beginning of coronary angiography. Those with definite indication for subsequent PCI will be given additional enoxaparin 0.25 mg/kg at the beginning of PCI (Staged-dose PCI Group [0.5+0.25 mg/kg]); while, those have no indication for subsequent PCI will not receive additional anticoagulation (Standard-dose Group [0.5 mg/kg]). All patients in the Planned Single-dose Group will receive enoxaparin 0.75 mg/kg at the beginning of coronary angiography no matter they will undergo subsequent PCI (Single-dose PCI Group [0.75 mg/kg]) or not (High-dose Group [0.75 mg/kg]).Eligible patients are randomly assigned into the Planned Staged-dose Group and the Planned Single-dose Group. All patients in the Planned Staged-dose Group will receive enoxaparin 0.5 mg/kg at the beginning of coronary angiography. Those with definite indication for subsequent PCI will be given additional enoxaparin 0.25 mg/kg at the beginning of PCI (Staged-dose PCI Group [0.5+0.25 mg/kg]); while, those have no indication for subsequent PCI will not receive additional anticoagulation (Standard-dose Group [0.5 mg/kg]). All patients in the Planned Single-dose Group will receive enoxaparin 0.75 mg/kg at the beginning of coronary angiography no matter they will undergo subsequent PCI (Single-dose PCI Group [0.75 mg/kg]) or not (High-dose Group [0.75 mg/kg]).

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention

Actual Study Start Date :

May 12, 2017

Anticipated Primary Completion Date :

Oct 1, 2021

Anticipated Study Completion Date :

Oct 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Enoxaparin (Staged-dose PCI Group) Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and additional enoxaparin 0.25 mg/kg at the beginning of PCI (i.e., insertion of guiding catheter).	Drug: Enoxaparin (Staged-dose PCI Group) Enoxaparin 0.5+0.25 mg/kg administered intravenously. Other Names: Clexane
Active Comparator: Enoxaparin (Single-dose PCI Group) Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and NO additional enoxaparin at the beginning of PCI (i.e., insertion of guiding catheter).	Drug: Enoxaparin (Single-dose PCI Group) Enoxaparin 0.75 mg/kg administered intravenously. Other Names: Clexane
Experimental: Enoxaparin (High-dose Group) Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).	Drug: Enoxaparin (High-dose Group) Enoxaparin 0.75 mg/kg administered intravenously. Other Names: Clexane
Active Comparator: Enoxaparin (Standard-dose Group) Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).	Drug: Enoxaparin (Standard-dose Group) Enoxaparin 0.5 mg/kg administered intravenously. Other Names: Clexane

Outcome Measures

Primary Outcome Measures

Anti-Xa level (CAG-90 min) in the High-dose vs. the Standard-dose group. [At 90 min after the first dose enoxaparin is given.]
The anti-Xa level (CAG-90 min) in the High-dose vs. the Standard-dose group.
Anti-Xa level (CAG-90 min) in the Staged-dose PCI vs. the Single-dose PCI group. [At 90 min after the first dose enoxaparin is given.]
The anti-Xa level (CAG-90 min) in the Staged-dose PCI vs. the Single-dose PCI group.

Secondary Outcome Measures

Anti-Xa level (CAG-10 min) in the High-dose vs. the Standard-dose group. [At 10 min after the first dose enoxaparin is given.]
The anti-Xa level (CAG-10 min) in the High-dose vs. the Standard-dose group.
Anti-Xa level (CAG-10 min) in the Staged-dose PCI vs. the Single-dose PCI group. [At 10 min after the first dose enoxaparin is given.]
The anti-Xa level (CAG-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.
Anti-Xa level (PCI-0 min) in the Staged-dose PCI vs. the Single-dose PCI group. [At 0 min (immediately before) PCI.]
The anti-Xa level (PCI-0 min) in the Staged-dose PCI vs. the Single-dose PCI group.
Anti-Xa level (PCI-10 min) in the Staged-dose PCI vs. the Single-dose PCI group. [At 10 min after the beginning of PCI.]
The anti-Xa level (PCI-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.
Anti-Xa level (PCI-End) in the Staged-dose PCI vs. the Single-dose PCI group. [At the end of PCI.]
The anti-Xa level (PCI-End) in the Staged-dose PCI vs. the Single-dose PCI group.
Target anticoagulation (CAG-90 min) in the High-dose vs. the Standard-dose group. [At 90 min after the first dose enoxaparin is given.]
The rate of target anticoagulation (CAG-90 min) in the High-dose vs. the Standard-dose group.
Target anticoagulation (CAG-90 min) in the Staged-dose PCI vs. the Single-dose PCI group. [At 90 min after the first dose enoxaparin is given.]
The rate of target anticoagulation (CAG-90 min) in the Staged-dose PCI vs. the Single-dose PCI group.
Target anticoagulation (CAG-10 min) in the High-dose vs. the Standard-dose group. [At 10 min after the first dose enoxaparin is given.]
The rate of target anticoagulation (CAG-10 min) in the High-dose vs. the Standard-dose group.
Target anticoagulation (CAG-10 min) in the Staged-dose PCI vs. the Single-dose PCI group. [At 10 min after the first dose enoxaparin is given.]
The rate of target anticoagulation (CAG-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.
Target anticoagulation (PCI-0 min) in the Staged-dose PCI vs. the Single-dose PCI group. [At 0 min (immediately before) PCI.]
The rate of target anticoagulation (PCI-0 min) in the Staged-dose PCI vs. the Single-dose PCI group.
Target anticoagulation (PCI-10 min) in the Staged-dose PCI vs. the Single-dose PCI group. [At 10 min after the beginning of PCI.]
The rate of target anticoagulation (PCI-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.
Target anticoagulation (PCI-End) in the Staged-dose PCI vs. the Single-dose PCI group. [At the end of PCI.]
The rate of target anticoagulation (PCI-End) in the Staged-dose PCI vs. the Single-dose PCI group.

Other Outcome Measures

Major adverse cardiac events (MACE) in the High-dose vs. the Standard-dose group. [Up to 24 hours.]
The proportion of patients with the composite of death, or myocardial infarction, or urgent coronary revascularization, or definite or probable stent thrombosis in the High-dose vs. the Standard-dose group.
Major adverse cardiac events (MACE) in the Staged-dose PCI vs. the Single-dose PCI group. [Up to 24 hours.]
The proportion of patients with the composite of death, or myocardial infarction, or urgent coronary revascularization, or definite or probable stent thrombosis in the Staged-dose PCI vs. the Single-dose PCI group.
Thrombolysis in myocardial infarction (TIMI) major or minor bleeding in the High-dose vs. the Standard-dose group. [Up to 24 hours.]
The proportion of patients with the composite of TIMI major or minor bleeding in the High-dose vs. the Standard-dose group.
Thrombolysis in myocardial infarction (TIMI) major or minor bleeding in the Staged-dose PCI vs. the Single-dose PCI group. [Up to 24 hours.]
The proportion of patients with the composite of TIMI major or minor bleeding in the Staged-dose PCI vs. the Single-dose PCI group.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Provision of written informed consent.
Aged 18 years or older, male or female.
Documented stable coronary artery disease (SCAD) or non-ST-segment elevation acute coronary syndromes (NSTE-ACS).
Plan to undergo elective trans-radial coronary angiography with or without subsequent PCI.
No fibrinolytic, or anticoagulant, or parenteral antiplatelet therapy within 7 days of screening.
Negative cardiac troponin test within 7 days of screening.
Trans-radial approach successfully established.
Females who are either post-menopausal > 1 year or surgically sterile.

Exclusion Criteria:

Recent (within 30 days of screening) acute myocardial infarction, including ST-segment elevation myocardial infarction or non-ST-segment elevation myocardial infarction.
The aim of the index coronary angiography is to undergo primary PCI or early PCI for acute coronary syndromes.
Any indications other than coronary artery disease (e.g., atrial fibrillation, prosthetic heart valve, venous thromboembolism, ventricular thrombosis, et al) for fibrinolytic or anticoagulant treatment during study period.
Planned use of any fibrinolytic or antithrombotic agents, with the exception of enoxaparin, aspirin, clopidogrel, and ticagrelor during study period.
Planned coronary artery bypass graft (CABG) during study period.
Increased bleeding risk, including

any history of intracranial, intraocular, retroperitoneal, or spinal bleeding;
recent (within 30 days of screening) gastrointestinal (GI) bleeding;
recent (within 30 days of screening) major trauma or major surgery;
planned surgery or other invasive procedure during study period;
sustained uncontrolled hypertension (systolic blood pressure [SBP] > 180 mmHg or diastolic blood pressure [DBP] > 100 mmHg) within 7 days of screening;
history of hemorrhagic disorders, e.g., haemophilia, von Willebrand's disease;
inability to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during study period;
platelet count less than 100,000/mm3 or hemoglobin < 10 g/dL within 7 days of screening.

Contraindications for enoxaparin, e.g., hypersensitivity, active bleeding, bleeding diathesis, coagulation disorders, acute infectious endocarditis, thrombocytopenia (including heparin-induced thrombocytopenia), cerebral hemorrhage, severe liver of kidney diseases, severe hypertension, stroke, retinopathy, et al.
History of intolerance to enoxaparin.
Patient requires dialysis or has a creatinine clearance < 30 mL/min as calculated by the Cockcroft-Gault equation: Clcr = (140 - Age) × WT / (72 × Scr) (× 0.85 for females), where WT is weight in kg, Scr is serum creatinine in mg/dL measured within 7 days of screening.
Any acute or chronic unstable conditions in the past 30 days which, in the opinion of the investigator, may either put the patient at risk or influence the result of the study, e.g., active cancer, et al.
Any condition that may increase the risk of non-compliance to study protocol or follow-up, e.g., history of drug addiction or alcohol abuse, et al.
Patients who has previously been randomized in this study.
Participation in another investigational drug or device study within 30 days of screening.
Involvement in the planning and conduct of the study (applies to investigators, contract research organization staff, and study site staff).
Known pregnancy, breast-feeding, or intend to become pregnant during the study period.
Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study.